Antiviral treatment for COVID-19: the evidence supporting remdesivir

Charlotte Richardson, Sanjay Bhagani and Gabriele Pollara
Download PDF
DOI: https://doi.org/10.7861/clinmed.2020-0524
Clin Med November 2020

Article Figures & Data

Tables

  • Box 1.

    NHS interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older)13

    Eligibility criteria (in accordance with the product licence):

    • Hospitalised with COVID-19

    • With pneumonia requiring supplemental oxygen

    • Adults, and adolescents ≥12 years of age and ≥40 kg

    • eGFR ≥30 ml/min

    • Alanine aminotransferase (ALT) below 5 times the upper limit of normal at baseline

    Remdesivir should be avoided in pregnancy unless clinicians believe the benefits of treatment outweigh the risks to the individual.
Back to top

Article Tools

Download PDF
Article Alerts
Citation Tools
Antiviral treatment for COVID-19: the evidence supporting remdesivir
Charlotte Richardson, Sanjay Bhagani, Gabriele Pollara
Clinical Medicine Nov 2020, 20 (6) e215-e217; DOI: 10.7861/clinmed.2020-0524
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section